Illumina 董事会批准 GRAIL 分拆并于 2024 年在纳斯达克上市，保留 14.5% 的股份。 Illumina's board approves GRAIL spin-off for Nasdaq listing in 2024, retaining 14.5% stake.

Illumina 董事会已批准于 2024 年 6 月 24 日分拆目前为子公司的癌症检测公司 GRAIL。 Illumina's board has approved the spin-off of cancer detection company GRAIL, currently a subsidiary, on June 24, 2024. GRAIL将申请在纳斯达克上市，股票代码为“GRAL”。 GRAIL will apply for listing on Nasdaq under the ticker "GRAL". Illumina 股东将保留其现有股份，并且每持有六股 Illumina 普通股将获得一股 GRAIL 普通股。 Illumina shareholders will retain their current shares and receive one share of GRAIL common stock for every six shares of Illumina common stock held. Illumina 将保留 GRAIL 14.5% 的少数股权。 Illumina will retain a 14.5% minority stake in GRAIL.